http://www.benzinga.com/node/add/storyPiper Jaffray Reports On ABMD's PROTECT II

Piper Jaffray has issue a report on the positive clinical trial results from Abiomed's ABMD PROTECT II study. According to the report, "While the trial did not achieve its primary endpoint, there were multiple aspects of it that were encouraging. In particular, in the cohort of patients that did not undergo atherectomy (88% of the study group), patients supported on Impella reported a statistically significant reduction in major adverse events at both 30 and 90 days compared to the control arm's intra aortic balloon pump (IABP). We believe the data will drive adoption of Impella in patients undergoing high risk PCI cases." ABMD has an Overweight Rating and a $15 Price Target. ABMD closed yesterday at $14.65 a share.